Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to...
-
CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to...
-
CAMBRIDGE, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to...
-
CAMBRIDGE, Mass., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to...
-
CAMBRIDGE, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to...
-
WT1 is a Well-Characterized Oncofetal Antigen, Expressed in Solid Tumors and Hematologic Malignancies CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma™, Inc., (NASDAQ: CUE) an...
-
CAMBRIDGE, Mass., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to...
-
CUE-101 Demonstrates Selective Binding and Preferential Activation/Expansion of Antigen-specific T Cells, Inhibition of Tumor Growth as Monotherapy and in Combination with a PD-1 Inhibitor CAMBRIDGE,...
-
Collaboration Expands Development and Manufacturing of Immuno-STAT™ Biologics and Broadens Coverage of Patient Populations CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma™, Inc....
-
CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma™, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to...